All In MedTech

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

2

PMA pathway

Device trials

4

Naming "Solia CSP S"

MAUDE reports

75

Brand "Solia CSP S", since 2015

PubMed studies

0

Mentioning "Solia CSP S"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Solia CSP S Leads

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 2 of 2 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Solia CSP S", any status and sponsor, newest update first.

Open in Trial Radar
  • Biotronik SE & Co. KGNot on our public-company list

    NCT07393009 · 1,000 participants (planned) · Start May 25, 2026 · Primary completion Feb 1, 2033

    Device: Implantation of the Solia CSP S pacing lead for LBBAP · For: Cardiac Pacing; Cardiac Pacemaker; Implantable Cardioverter Defibrillator and 4 more

    Sites: Adelaide, Australia; Melbourne, Australia; Linz, Austria · 46 sites in all

  • BIO|MASTER.CSP StudyPivotal-lookingActive, not recruiting

    Biotronik SE & Co. KGNot on our public-company list

    NCT06620237 · 152 participants (planned) · Start Oct 4, 2024 · Primary completion Oct 2026

    Device: Implantation of the Solia CSP S pacing lead for LBBAP · For: Cardiac Pacing, Artificial; Cardiac Pacemaker, Artificial; Cardiac Resynchronization Therapy Devices and 4 more

    Sites: Adelaide, Australia; Clayton, Australia; Elizabeth Vale, Australia · 14 sites in all

  • CSP-SOLIA-REGISTRYNot yet recruiting

    Hospital SOS CardioResearch network

    NCT07808554 · 300 participants (planned) · Start Nov 2, 2026 · Primary completion Mar 2, 2028

    Device: Solia CSP S Lead · For: Left Bundle Branch Area Pacing

1 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Solia CSP S", and for the whole product code for context.

This brand

75 reports: 1 malfunction, 74 injury, 0 death

Whole product code NVN

202,094 reports: 87,136 malfunction, 110,708 injury, 4,019 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "Solia CSP S"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

No PubMed record mentions this device by name.

Other devices of this type

Also filed under product code NVN.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.